1. Describing the diagnosis and clinical classification of Pulmonary Hypertension, according to the 7th World Symposium and recent 2022 ERS/ESC guideline updates, as well as the treatment options with respect to PAH-specific therapies.

2. Recognize how PH patient characteristics and phenotypes may change over the patient’s lifespan as patients with PAH are living longer and may develop cardiovascular and other comorbidities associated with older age.

3. Recognizing current and emerging tools, as well as gaps and opportunities to enhance the screening, detection and ultimate diagnosis of PAH.

4. Learning about patient reported outcome tools that exist to assess health related quality of life in PH, and how these might be applied in research and routine clinical care. Also recognize how they may further the goal of providing patient-centered care shared decision-making.

5. Learning about best practices for the procedure, as well as emerging research on additional metrics to inform patient diagnosis and prognosis.

6. Recognizing how social determinants of health intersecting with other patient factors such as race, ethnicity, and socioeconomic status may shape outcomes in patients with PH.

7. Understanding and recognition of nuanced clinical situations in which the role and management of PAH therapy can be challenging to determine and navigate.

8.Learning approaches to manage these patient scenarios from PH center expert clinicians.

9. Learning about the past and current approaches to PAH clinical trial design to enable the investigation and potential approval of new candidate PAH therapies.

10.Discussing what may be needed for trials to evolve as the treatment landscape for PAH changes in the future.